Literature DB >> 20470007

Clinical applications of PET and PET/CT in pediatric malignancies.

Rakesh Kumar1, Varun Shandal, Shamim Ahmed Shamim, Dhanapathi Halanaik, Arun Malhotra.   

Abstract

The common childhood cancers are leukemia, CNS tumors, lymphomas, soft-tissue tumors (such as rhabdomyosarcoma and fibrosarcoma), neuroblastoma, malignant bone tumors, germ cell tumors with neoplasms of gonads and hepatic tumors. Usually the conventional imaging modalities, such as x-ray, ultrasound, computed tomography (CT) and MRI, are being routinely used for the management of these pediatric malignancies. However, most of these modalities provide structural information and are lacking in functional/metabolic status of these malignancies. Recently, PET and PET/CT have emerged as a functional diagnostic imaging modality for the management of various cancers in adult population. Up to now most of the data published in the literature are on PET alone. PET used in conjunction with CT is useful as it provides an enhanced view of the anatomical details and the malignant focus then can be located with highest accuracy. PET and PET/CT has been found to be useful in, for example, CNS tumors, lymphomas, soft-tissue tumors, neuroblastoma, malignant bone tumors and germ cell tumors. PET/CT has a limited role in early diagnosis, however, it plays an important role in initial staging, treatment response evaluation and detection of metastatic disease in these cancers. Despite the fact that PET/CT has better diagnostic value when compared with conventional imaging, such as CT and MRI, in the management of many pediatric cancers, there are certain limitations. PET/CT has a limited role in detection of lesions smaller than 5 mm, well-differentiated tumors and tumors with low metabolic rate. Many infections and inflammation can lead to false-positive PET/CT results. In the present review we will discuss the various clinical indications of PET and PET/CT in pediatric cancers.

Entities:  

Mesh:

Year:  2010        PMID: 20470007     DOI: 10.1586/era.10.12

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  8 in total

Review 1.  Positron emission tomography for benign and malignant disease.

Authors:  Anthony Visioni; Julian Kim
Journal:  Surg Clin North Am       Date:  2011-02       Impact factor: 2.741

2.  Detection of a metastatic lesion and tiny yolk sac tumors in two teenage patients by FDG-PET: report of two cases.

Authors:  Masataka Takahashi; Yutaka Kanamori; Miwako Takahashi; Toshimitsu Momose; Tadashi Iwanaka
Journal:  Surg Today       Date:  2013-06-26       Impact factor: 2.549

Review 3.  2-deoxy-2-((18)F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology.

Authors:  John Freebody; Eva A Wegner; Monica A Rossleigh
Journal:  World J Radiol       Date:  2014-10-28

Review 4.  Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.

Authors:  Bas Vaarwerk; Willemijn B Breunis; Lianne M Haveman; Bart de Keizer; Nina Jehanno; Lise Borgwardt; Rick R van Rijn; Henk van den Berg; Jérémie F Cohen; Elvira C van Dalen; Johannes Hm Merks
Journal:  Cochrane Database Syst Rev       Date:  2021-11-09

5.  Successful use of metronomic vinblastine and fluorothymidine pet imaging for the management of intramedullary spinal cord anaplastic oligoastrocytoma in a child.

Authors:  R Demlova; K Melicharkova; Z Rehak; L Kren; H Oslejskova; J Sterba
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

6.  PET/MRI in cancer patients: first experiences and vision from Copenhagen.

Authors:  Andreas Kjær; Annika Loft; Ian Law; Anne Kiil Berthelsen; Lise Borgwardt; Johan Löfgren; Camilla Bardram Johnbeck; Adam Espe Hansen; Sune Keller; Søren Holm; Liselotte Højgaard
Journal:  MAGMA       Date:  2012-12-25       Impact factor: 2.310

7.  Investigation of dose minimisation protocol for 18F-FDG PET-CT in the management of lymphoma postchemotherapy followup.

Authors:  L I Sonoda; B Sanghera; W L Wong
Journal:  ScientificWorldJournal       Date:  2012-04-01

8.  Diagnostic performance of 18F-FDG PET/CT and whole-body diffusion-weighted imaging with background body suppression (DWIBS) in detection of lymph node and bone metastases from pediatric neuroblastoma.

Authors:  Hiroaki Ishiguchi; Shinji Ito; Katsuhiko Kato; Yusuke Sakurai; Hisashi Kawai; Naotoshi Fujita; Shinji Abe; Atsushi Narita; Nobuhiro Nishio; Hideki Muramatsu; Yoshiyuki Takahashi; Shinji Naganawa
Journal:  Ann Nucl Med       Date:  2018-04-17       Impact factor: 2.668

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.